News
Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...
Aflibercept 8mg (0.07mL of 114.3mg ... Using aseptic technique the intravitreal injection should be performed with a 30-gauge x ½-inch injection needle. Each vial should only be used to treat a ...
1d
Clinical Trials Arena on MSNANI Pharmaceuticals reports outcomes from diabetic macular oedema trialThe trial subjects were adults with either type 1 or type 2 diabetes, exhibiting central involvement in diabetic macular ...
In this Healio Video Perspective from the ARVO meeting, Michael Javaheri, MD, overviews real-world data on Eylea HD in ...
2d
TipRanks on MSNANI Pharmaceuticals reports results from clinical trial of IluvienANI Pharmaceuticals (ANIP) announced results from the NEW DAY clinical trial of ILUVIEN, or fluocinolone acetonide intravitreal implant, 0.19 mg ...
In ANI's New Day trial, patients were randomized to an induction phase to receive either a single Iluvien injection or a series of five monthly injections of aflibercept, followed by supplemental ...
ANI Pharmaceuticals (ANIP) stock drops as its Iluvien implant fails in a clinical trial versus Eylea marketed by Regeneron ...
The prefilled syringe requires fewer preparation steps than the vial. A prefilled syringe formulation of Elyea (aflibercept injection) has been made available by Regeneron. Eylea, a vascular ...
(RTTNews) - Sandoz (SDZNY) said that the European Commission has granted marketing authorization for Afqlir (aflibercept) 2 mg vial kit and pre-filled syringe for intravitreal injection, a ...
EYLEA ® (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein ...
Syringes prefilled with aflibercept by the manufacturer may cause elevated intraocular pressure (IOP) after intravitreal injection, the European Medicines Agency (EMA) is warning. The agency has ...
On August 18, 2023, Regeneron Pharmaceuticals, Inc. (“Regeneron”) announced that the FDA approved EYLEA HD®, an 8 mg injection of EYLEA® (aflibercept). EYLEA HD®, jointly developed with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results